论文信息 - 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067) - 字舞流文

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

J. Wolchok | J. Larkin | F. Hodi | J. Schachter | J. Grob | V. Chiarion-Sileni | R. Gonzalez | D. Hogg | P. Lorigan | C. Lebbé | M. Carlino | J. Wagstaff | J. Hassel | P. Wolter | C. Lao | L. Thomas | A. Hill | D. Walker | C. L. Cowey | Joel Jiang